Longer Term Data Confirm Subcutaneous Rituximab Efficacy in Follicular Lymphoma
In this video we discuss longer term results of the phase III SABRINA study, which tested the safety and efficacy of subcutaneous rituximab in patients with follicular lymphoma.
The availability of subcutaneous rituximab, which takes less than 10 minutes to administer, offers convenience for both patients and healthcare professionals compared with rituximab delivered intravenously.
Longer term safety and efficacy data (median follow-up = 37 months) from the phase III SABRINA study, which examined subcutaneous rituximab in treatment-naive follicular lymphoma patients, were presented at the 2016 American Society of Hematology (ASH) Annual Meeting, held December 3–6 in San Diego, California.
In this video Andrew Davies, PhD, of the University of Southampton and Cancer Research UK, discusses the findings.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Low Rates of Chronic Graft-Versus-Host Disease With Ruxolitinib Maintenance Following Allogeneic HCT
June 2nd 2025Researchers conducted a prospective, multicenter phase II clinical trial demonstrating that prolonged administration of ruxolitinib after allogeneic HCT is associated with notably low rates of cGVHD.
